@author-1788515151757110
Zuo Yi Technology's future roadmap centers on "proactive artificial intelligence." An AI doctor should not merely be a tool that responds passively, but rather an active health partner that intervenes on its own initiative.
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Future Intelligent focuses on R&D and scenario innovation for AI-powered office hardware.
The ranking aims to offer an objective lens for understanding application trends in China's generative AI space, spotlighting early adopters and benchmark cases that dare to experiment and innovate.
The "ChinaVenture Rankings" have been published for 19 consecutive years, recognized within the industry for their professionalism, authority, and rigor. They are widely regarded as a bellwether for China's equity investment sector and serve as a key reference for capital commitments from many large institutional LPs.
This study, the world's first Phase 3 clinical trial covering RSV-infected infants under six months of age, successfully fills the evidence gap for targeted treatment approaches in this high-risk population and provides critical evidence for building a comprehensive RSV disease management system.
The rankings prioritize technical capability and commercialization potential, offering a panoramic survey of China's systematic breakthroughs in AI technology.
Following Qiming Venture Partners' portfolio companies' milestone moments with you
As China's first independently developed gene therapy for hemophilia B, Xinjiuning® will offer patients a completely new treatment option, with the potential to free them from a lifetime of frequent intravenous injections and help them return to a life without constraints.
